Company Filing History:
Years Active: 2001
Title: **Philippe Bastard: Pioneering Pharmaceutical Innovations in Montpellier**
Introduction
Philippe Bastard is an innovative inventor located in Montpellier, France. He has made significant contributions to the field of pharmaceuticals through his research and development efforts. With one patent to his name, Philippe continues to push the boundaries of knowledge and technology in the medical field.
Latest Patents
Philippe's noteworthy patent is titled "Pharmaceutical composition for oral administration." This invention involves an aqueous solution containing 1-[2-(2-naphthyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine hydrochloride (hydrochloride of SR 57746). The composition also includes β-cyclodextrin (β-CD) and a pharmaceutically acceptable acid or buffer to maintain a pH of less than or equal to 3. This formulation aims to enhance the efficacy and stability of the pharmaceutical product, showcasing Philippe's dedication to improving therapeutic options.
Career Highlights
Philippe Bastard has made a mark in the pharmaceutical industry through his work with Sanofi-Synthelabo. His role at this prominent company has allowed him to collaborate on various projects, furthering his expertise and contributing to groundbreaking innovations. His singular patent highlights his capacity to identify and solve complex challenges in drug formulation.
Collaborations
Throughout his career, Philippe has had the privilege of working alongside esteemed colleagues such as Claude Aleman and Marielle Bonnel. Their collaborative efforts in research and development have fostered an environment of creativity and innovation, ultimately leading to advancements in pharmaceutical sciences.
Conclusion
Philippe Bastard exemplifies the spirit of innovation in the pharmaceutical industry. His patented work underscores his commitment to addressing medical needs through scientific exploration and collaboration. As he continues his journey at Sanofi-Synthelabo, Philippe's contributions are likely to have a lasting impact on the future of healthcare.